Idhifa/enasidenib Cost, Side effects, Dosage, Uses for acute myeloid leukemia

Read about Idhifa/enasidenib Cost, Side effects, Dosage, Uses for acute myeloid leukemia.The FDA granted the approval of Idhifa to Celgene Corporation

US FDA approved new drug idhifa that contains active pharmaceutical ingredient enasidenib for the treatment of acute myeloid leukemia (AML) in adult patients who have relapsed of AML due to mutation in specific gene. US FDA indicated this drug along with specific assay to identify mutations IDH2 gene before initiating specific therapy.

Leukemia is a group of cancers that usually affect bone marrow. All types of leukemia tend to increase immature white blood cells. Research is still in process to find out exact underlying cause of leukemia but many researchers believe that genetic predisposition and environmental factors are key factors in the pathogenesis of leukemia. These factors include continuous exposure to certain toxic
chemicals in plants and factories, exposure to radiations, smoking, viral infections etc.

There are four major types of leukemia commonly identified in patients. These are acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). Survival rate of leukemia mainly depends upon patient age and type leukemia.  

Idhifa/enasidenib is IDH-2 (isocitrate dehydrogenase-2) inhibitor that blocks enzymes responsible proliferation of immature white blood cells in case of acute myeloid leukemia. This drug must be used in case of detection of IDH2 gene mutations via RealTime IDH2 Assay.


Idhifa/enasidenib Cost, Side effects, Dosage, Uses for acute myeloid leukemia


Idhifa/enasidenib side effects


According to health authorities following side effects were reported during clinical trails

  • Fever
  • Difficulty in breathing
  • Acute respiratory distress
  • Inflammation in lungs
  • Fluid accumulation in lungs
  • Weight gain
  • Metabolic changes
  • Swelling
  • Abdominal pain
  • hepatic and renal impairment


Idhifa/enasidenib Uses


US FDA indicated Idhifa/enasidenib for the treatment of acute myeloid leukemia (AML) in adult patients who have relapsed of AML due to mutation in specific gene. US FDA indicated this drug along with specific assay to identify mutations IDH2 gene before initiating specific therapy.

Idhifa/enasidenib Cost and Dosage


According to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Share this

Related Posts

Previous
Next Post »

Leave a reply